The average pre-money IPO step up for US biotech companies that have hit the public markets in this last financing window is 2.11. We've pointed out in this space that biotech investors are saving their money for companies with Phase III products—the only development stage which peaks above this modest average, at 2.60 (see "Biotech Investors: Believing the Dream, Rewarding Phase III IPOs," START-UP, November 2004 Also see "Biotech Investors: Believing the Dream, Rewarding Phase III IPOs" - Scrip, 1 November, 2004.).
But not all Phase III products are alike, and an analysis of these same companies suggests that investors prefer certain...







